Commerce Bank trimmed its position in Novartis AG (NYSE:NVS) by 6.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 26,577 shares of the company’s stock after selling 1,692 shares during the period. Commerce Bank’s holdings in Novartis were worth $2,290,000 at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. Commerzbank Aktiengesellschaft FI boosted its holdings in Novartis by 13.7% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 48,425 shares of the company’s stock worth $3,658,000 after buying an additional 5,823 shares during the last quarter. Fosun International Ltd acquired a new stake in Novartis in the 2nd quarter worth about $468,000. Neuburgh Advisers LLC boosted its holdings in Novartis by 13.0% in the 2nd quarter. Neuburgh Advisers LLC now owns 22,984 shares of the company’s stock worth $1,736,000 after buying an additional 2,652 shares during the last quarter. Carillon Tower Advisers Inc. boosted its holdings in Novartis by 16.9% in the 2nd quarter. Carillon Tower Advisers Inc. now owns 163,661 shares of the company’s stock worth $12,363,000 after buying an additional 23,605 shares during the last quarter. Finally, Cox Capital Co LLC acquired a new stake in Novartis in the 2nd quarter worth about $1,399,000. Institutional investors own 10.95% of the company’s stock.
Several equities research analysts recently issued reports on NVS shares. ValuEngine upgraded Novartis from a “strong sell” rating to a “sell” rating in a report on Thursday, July 19th. DZ Bank reissued a “buy” rating on shares of Novartis in a research note on Thursday, July 19th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novartis in a research note on Thursday, July 19th. Barclays raised shares of Novartis from an “underweight” rating to an “equal weight” rating in a research note on Thursday, July 19th. Finally, Zacks Investment Research lowered shares of Novartis from a “hold” rating to a “sell” rating in a research note on Wednesday, August 29th. Twelve analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $84.86.
Novartis (NYSE:NVS) last released its earnings results on Thursday, October 18th. The company reported $1.32 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.31 by $0.01. Novartis had a net margin of 25.98% and a return on equity of 15.81%. The business had revenue of $12.78 billion for the quarter, compared to analyst estimates of $12.88 billion. During the same period last year, the company posted $1.29 EPS. The business’s revenue was up 2.9% on a year-over-year basis. Sell-side analysts forecast that Novartis AG will post 5.17 EPS for the current fiscal year.
Novartis Company Profile
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.
Featured Article: Market Capitalization
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.